Paragon Biosciences
Chicago-based Paragon innovates in life sciences, focusing on AI, gene therapy, synthetic biology, and biopharmaceuticals.
- 26
- Company
- Chicaco, IL, USUnited States
Chicago-based Paragon innovates in life sciences, focusing on AI, gene therapy, synthetic biology, and biopharmaceuticals.
paragonbiosci.comCrawled Oct 14, 2026
News Room News Room News Room Archives
The company aims to foster innovation, collaboration and results. Its team includes people from diverse backgrounds and career paths.
Paragon launches companies using a portfolio approach to science and its expertise in clinical development, regulatory affairs, manufacturing and commercialization.
Paragon Biosciences, founded by Jeff Aronin, creates, builds and funds biology-based companies to accelerate scientific breakthroughs in treating and curing diseases.
Paragon creates, builds and funds biology-based companies to treat and cure diseases.
Terms of Use - Paragon Biosciences
Paragon sells Emalex to Teva Pharmaceutical Industries for $900 million. The deal reflects Paragon’s strategy of developing bioscience companies to a stage where their research is ready for acquisition. Emalex’s technology, focused on neurological treatments, now transitions under Teva’s pharmaceutical portfolio.
Jun 2026chicagobusiness.comNews article
Emalex Biosciences secures **$35 million in Series C Preferred Stock** to accelerate clinical trials for **Tourette syndrome** and **stuttering**. The funding round is led by **Paragon Biosciences**, with participation from **Fidelity Management & Research** and **Valor Equity Partners**. The company focuses on developing treatments for central nervous system movement and fluency disorders.
Mar 2021BioSpaceNews article
Paragon Biosciences launches **CiRC Biosciences**, a new entity to bolster its cell and gene therapy platform. The move aligns with the company’s strategy of developing and investing in biopharmaceutical ventures. CiRC Biosciences will focus on advancing therapeutic solutions within Paragon’s broader ecosystem.
Feb 2021PR NewswireNews article
Castle Creek Biosciences secures $75 million to accelerate gene therapy candidates targeting rare diseases with significant unmet medical needs. The company uses its proprietary technology and manufacturing platform to develop treatments for multiple conditions. This funding supports further clinical and operational progress in gene-based therapies.
Mar 2020GlobeNewswireNews article